|
1
|
Carmeliet P and Jain RK: Principles and
mechanisms of vessel normalization for cancer and other angiogenic
diseases. Nat Rev Drug Discov. 10:417–427. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Folkman J: Angiogenesis: an organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jain RK, Duda DG, Clark JW and Loeffler
JS: Lessons from phase III clinical trials on anti-VEGF therapy for
cancer. Nat Clin Prac Oncol. 3:24–40. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ng EWM, Shima DT, Calias P, Cunningham ET,
Guyer DR and Adamis AP: Pegaptanib, a targeted anti-VEGF aptamer
for ocular vascular disease. Nat Rev Drug Discov. 5:123–132. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brown DM and Regillo CD: Anti-VEGF agents
in the treatment of neovascular age-related macular degeneration:
applying clinical trial results to the treatment of everyday
patients. Am J Ophthalmol. 144:627–637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stetler-Stevenson WG: Matrix
metalloproteinases in angiogenesis: a moving target for therapeutic
intervention. J Clin Invest. 103:1237–1241. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bourboulia D and Stetler-Stevenson WG:
Matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs): positive and negative regulators in
tumor cell adhesion. Semin Cancer Biol. 20:161–168. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brew K and Nagase H: The tissue inhibitors
of metalloproteinases (TIMPs): an ancient family with structural
and functional diversity. Biochim Biophys Acta. 1803:55–71. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stetler-Stevenson WG: Tissue inhibitors of
metalloproteinases in cell signaling: metalloproteinase-independent
biological activities. Sci Signal. 1:re62008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seo DW, Li H, Guedez L, et al: TIMP-2
mediated inhibition of angiogenesis: an MMP-independent mechanism.
Cell. 114:171–180. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qi JH, Ebrahem Q, Moore N, et al: A novel
function for tissue inhibitor of metalloproteinases-3 (TIMP3):
inhibition of angiogenesis by blockage of VEGF binding to VEGF
receptor-2. Nat Med. 9:407–415. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jung KK, Liu XW, Chirco R, Fridman R and
Kim HRC: Identification of CD63 as a tissue inhibitor of
metalloproteinase-1 interacting cell surface protein. EMBO J.
25:3934–3942. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim SH, Cho YR, Kim HJ, et al: Antagonism
of VEGF-A-induced increase in vascular permeability by an integrin
α3β1-Shp-1-cAMP/PKA pathway. Blood. 120:4892–4902. 2012.PubMed/NCBI
|
|
15
|
Ryu JH, Ahn H and Jin Lee H: Inhibition of
nitric oxide production on LPS-activated macrophages by kazinol B
from Broussonetia kazinoki. Fitoterapia. 74:350–354. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cha JY, Kim YT, Kim HS and Cho YS:
Antihyperglycemic effect of stem bark powder from paper mulberry
(Broussonetia kazinoki Sieb.) in type 2 diabetic Otsuka
Long-Evans Tokushima fatty rats. J Med Food. 11:499–505. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee JK, Ha H, Lee HY, et al: Inhibitory
effects of heartwood extracts of Broussonetia kazinoki Sieb
on the development of atopic dermatitis in NC/Nga mice. Biosci
Biotechnol Biochem. 74:1802–1806. 2010.PubMed/NCBI
|
|
18
|
Ko HH, Yen MH, Wu RR, Won SJ and Lin CN:
Cytotoxic isoprenylated flavans of Broussonetia kazinoki. J
Nat Prod. 62:164–166. 1998. View Article : Google Scholar
|
|
19
|
Zhang PC, Wang S, Wu Y, Chen RY and Yu DQ:
Five new diprenylated flavonols from the leaves of Broussonetia
kazinoki. J Nat Prod. 64:1206–1209. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim HJ, Cho YR, Kim SH and Seo DW:
TIMP-2-derived 18-mer peptide inhibits endothelial cell
proliferation and migration through cAMP/PKA-dependent mechanism.
Cancer Lett. 343:210–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seo DW, Cho YR, Kim W and Eom SH:
Phytochemical linarin enriched in the flower of Chrysanthemum
indicum inhibits proliferation of A549 human alveolar basal
epithelial cells through suppression of the Akt-dependent signaling
pathway. J Med Food. 16:1086–1094. 2013.PubMed/NCBI
|
|
22
|
Cho YR, Kim JK, Kim J, Oh J and Seo DW:
Ligularia fischeri regulates lung cancer cell proliferation
and migration through down-regulation of epidermal growth factor
receptor and integrin β1 expression. Genes Genom. 35:741–746. 2013.
View Article : Google Scholar
|
|
23
|
Seo DW, Kim SH, Eom SH, et al: TIMP-2
disrupts FGF-2-induced downstream signaling pathways. Microvasc
Res. 76:145–151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seo DW, Li H, Qu CK, et al: Shp-1 mediates
the antiproliferative activity of tissue inhibitor of
metalloproteinase-2 in human microvascular endothelial cells. J
Biol Chem. 281:3711–3721. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cho YR, Kim S, Ko H, Kim MD, Choi S and
Seo DW: Sepiapterin inhibits cell proliferation and migration of
ovarian cancer cells via down-regulation of
p70S6K-dependent VEGFR-2 expression. Oncol Rep.
26:861–867. 2011.PubMed/NCBI
|
|
26
|
Yoon HJ, Cho YR, Joo JH and Seo DW:
Knockdown of integrin α3β1 expression induces proliferation and
migration of non-small cell lung cancer cells. Oncol Rep.
29:662–668. 2013.
|
|
27
|
Cho YR, Choi S and Seo DW: The in
vitro antitumor activity of Siegesbeckia glabrescens
against ovarian cancer through suppression of receptor tyrosine
kinase expression and the signaling pathways. Oncol Rep.
30:221–226. 2013.
|
|
28
|
Lee HN, Joo JH, Oh JS, Choi SW and Seo DW:
Regulatory effects of Siegesbeckia glabrescens on non-small
cell lung cancer cell proliferation and invasion. Am J Chin Med.
42:453–463. 2014.
|
|
29
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ellis LM and Hicklin DJ: VEGF-targeted
therapy: mechanisms of anti-tumour activity. Nat Rev Cancer.
8:579–591. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lemmon MA and Schlessinger J: Cell
signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wei BL, Chen YC and Hsu HY: Kazinol Q from
Broussonetia kazinoki enhances cell death induced by Cu(ll)
through increased reactive oxygen species. Molecules. 16:3212–3221.
2011.PubMed/NCBI
|
|
33
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling - in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
